Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
65.62 USD | +0.12% | -2.06% | -8.38% |
May. 16 | Transcript : Intra-Cellular Therapies, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 09:20 AM | |
May. 07 | Sector Update: Health Care Stocks Steady Pre-Bell Tuesday | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-8.38% | 6.92B | D+ | ||
-2.55% | 90.28B | A- | ||
-1.97% | 39.5B | A- | ||
-15.47% | 31.71B | B- | ||
+61.28% | 26.41B | A | ||
-22.81% | 14.34B | C | ||
-8.82% | 12.89B | B- | ||
-11.77% | 11.8B | D+ | ||
-45.97% | 10.95B | B | ||
+3.30% | 8.85B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ITCI Stock
- Ratings Intra-Cellular Therapies, Inc.